- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00409591
Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand (PHPT-5)
Maternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand.
Study Overview
Status
Conditions
Detailed Description
Multicenter, placebo-controlled, double blind, clinical trial where non immunocompromised women receiving the ZDV prophylaxis regimen from 28 weeks gestation, as recommended in Thailand, will be randomized to one of two arms:
Arm 1: NVP-NVP:
- In women, one NVP 200 mg tablet at onset of labor+;
- In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours+++
Arm 2: PL-NVP:
- In women, one placebo tablet at onset of labor++;
- In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours+++
Arm 3: LPV/r:
In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
- women in Arm 1 will also receive 7-day ZDV 300mg bid plus 3TC 150mg bid from delivery. ++women in Arm 2 will also receive 7-day (ZDV+3TC) Placebo from delivery. +++If the new born weight less than 2500 g, nevirapine will be administered 2 mg./1 kg (As per Thai Guideline).
All infants will receive ZDV for at least one week. Follow-up of women and infants is carried out on an outpatient basis except for delivery and the first three days after delivery. Mothers and infants are followed-up for 24 months after delivery.
Note: The study was stopped and data unblinded upon DSMB recommendations in September 2010 because of changes in Thai PMTCT guidelines recommending use of HAART in all HIV infected pregnant women regardless of their CD4 count. At the time of unblinding 435 pregnant women had been enrolled and follow-up of these women and their children is continuing.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10220
- Health Promotion Hospital Regional Center I
-
Chiang Mai, Thailand, 50100
- Health Promotion Center Region 10,
-
Chiang Mai, Thailand, 50110
- Fang Hospital
-
Chiang Mai, Thailand, 50160
- Chomthong hospital
-
Chonburi, Thailand, 20180
- Somdej Pranangchao Sirikit Hospital
-
Khon Kaen, Thailand, 40000
- Regional Health Promotion Centre 6,
-
Lamphun, Thailand, 51000
- Lamphun Hospital
-
Phayao, Thailand, 56000
- Phayao Provincial Hospital
-
Phuket, Thailand, 83000
- Vachira Phuket Hospital
-
Samutprakarn, Thailand, 10280
- Samutprakarn Hospital
-
-
Bangkok
-
Kannayao, Bangkok, Thailand, 10230
- Nopparat Rajathanee Hospital
-
Saimai, Bangkok, Thailand
- Bhumibol Adulyadej Hospital
-
-
Chachoengsao
-
Muang, Chachoengsao, Thailand, 24000
- Chachoengsao Hospital
-
-
Chantaburi
-
Muang, Chantaburi, Thailand, 22000
- Prapokklao Hospital
-
-
Chiang Mai
-
Mae Rim, Chiang Mai, Thailand, 50180
- Nakornping Hospital
-
Sanpatong, Chiang Mai, Thailand
- Sanpatong Hospital
-
-
Chiang Rai
-
Mae Chan, Chiang Rai, Thailand
- Mae Chan Hospital
-
Mae Sai, Chiang Rai, Thailand
- Mae Sai Hospital
-
Phan, Chiang Rai, Thailand
- Phan Hospital
-
-
Chiangrai
-
Chiang Saen, Chiangrai, Thailand, 57150
- Chiang Saen Hospital
-
Muang, Chiangrai, Thailand, 57000
- Chiangrai Prachanukroh Hospital
-
Wiangpapao, Chiangrai, Thailand, 57170
- Wiangpapao Hospital
-
-
Chonburi
-
Banglamung, Chonburi, Thailand, 20150
- Banglamung Hospital
-
Muang, Chonburi, Thailand, 20000
- Chonburi Hospital
-
Panasnikom, Chonburi, Thailand, 20140
- Panasnikom Hospital
-
Sri Racha, Chonburi, Thailand, 20230
- Ao Udom Hospital
-
-
Kalasin
-
Muang, Kalasin, Thailand, 46000
- Kalasin Hospital
-
-
Kanjanaburi
-
Munag, Kanjanaburi, Thailand, 71000
- Phaholpolphayuhasena Hospital
-
-
Khon Kaen
-
Muang, Khon Kaen, Thailand
- Khon Kaen Hospital
-
-
Lampang
-
Muang, Lampang, Lampang, Thailand, 52000
- Lampang Hospital
-
-
Mahasarakam
-
Muang, Mahasarakam, Thailand, 44000
- Mahasarakam Hospital
-
-
Nakhon Si Thammarat
-
Muang, Nakhon Si Thammarat, Thailand, 80000
- Maharaj Nakhon Si Thammarat Hospital
-
-
Nakhonpathom
-
Muang, Nakhonpathom, Thailand
- Nakhonpathom Hospital
-
-
Nong Kai
-
Muang, Nong Kai, Thailand, 43000
- Nong Khai Hospital
-
-
Nonthaburi
-
Muang, Nonthaburi, Thailand
- Pranangklao Hospital
-
-
Pathumthani
-
Muang, Pathumthani, Thailand, 12000
- Pathumthani Hospital
-
-
Phayao
-
Chiang Kham, Phayao, Thailand, 56110
- Chiang Kham Hospital
-
-
Pitsanulok
-
Muang, Pitsanulok, Thailand
- Buddhachinaraj Hospital
-
-
Rayong
-
Muang, Rayong, Thailand, 21000
- Rayong Hospital
-
-
Samutsakhon
-
Muang, Samutsakhon, Thailand, 74000
- Samutsakhon Hospital
-
-
Songkhla
-
Muangsongkhla, Songkhla, Thailand, 90100
- Songkhla Hospital
-
-
Songkla
-
Hat Yai, Songkla, Thailand, 90110
- Hat Yai Hospital
-
-
Trat
-
Muang, Trat, Thailand, 23000
- Trat Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Pre-Entry Criteria
- Evidence of HIV infection (documented by two HIV antibody tests on two different dates)
- Intend to be followed at a study site for the duration of the study
- At least 18 years old
- Written informed consent.
Inclusion Criteria:
Women are eligible for the study if they
- met all pre-entry criteria
- Evidence of HIV infection, as documented by two serology tests obtained at two different dates;
- between 28 and 36 weeks gestational age;
- antiretroviral naïve except for exposure to ZDV prophylaxis PMTCT;
- CD4 count above 250 cells/mm3 (within 4 months prior to randomization)
- agreement not to breastfeed;
- consent to participate and to be followed for the duration of the study;
- and the following laboratory values within 14 days prior to randomization:
- hemoglobin > 8.5 mg/dl;
- absolute neutrophil count > 750 cells/mm3;
- platelets > 50,000 cells/mm3;
- SGPT ≤ 5 times upper limit of normal;
- serum creatinine ≤ 1.5 times upper limit of normal (women with a serum creatinine > 1.5 times upper limit of normal must have a measured eight-hour urine creatinine clearance > 70 ml/min).
Exclusion criteria:
- Evidence of pre-existing fetal anomalies incompatible with life;
- patients who meet the criteria of Classes III/IV of the WHO classification of HIV-associated clinical disease;
- known hypersensitivity to any benzodiazepine;
- active tuberculosis;
- concurrent participation to any other clinical trial;
- receipt of benzodiazepines or antiretroviral agent other than ZDV;
- uncontrolled hypertension;
- anticoagulant therapy or magnesium sulfate within 2 weeks of enrollment or the need for them during labor or at delivery.
If any of these conditions occurs after randomization, the women will be excluded from study drug dosing. Women with CD4 count lower than 250 cells/mm3 will be excluded from the study and offered HAART in the context of the national program.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
NVP-NVP:
|
In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
|
Experimental: 2
PL-NVP:
|
In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
Comparison between Arms 1 and 2 is double-blinded. |
Experimental: 3
LPV/r:
|
In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Definitive HIV infection in infants as assessed by positive HIV DNA PCR on two peripheral blood samples
Time Frame: At birth, 7-10 days, 1, 2, 4 and 6 months of age
|
At birth, 7-10 days, 1, 2, 4 and 6 months of age
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety for mothers and children of two NVP doses in neonates with and without maternal single dose NVP at onset of labor or LPV/r from 28 weeks gestation.
Time Frame: From randomization during pregnancy until 24 months after delivery
|
From randomization during pregnancy until 24 months after delivery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marc Lallemant, MD, Institut de Recherche pour le Developpment
Publications and helpful links
General Publications
- Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, Kanshana S, McIntosh K, Thaineua V; Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004 Jul 15;351(3):217-28. doi: 10.1056/NEJMoa033500. Epub 2004 Jul 9.
- Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M; Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004 Jul 15;351(3):229-40. doi: 10.1056/NEJMoa041305. Epub 2004 Jul 9.
- Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, Stevens L, Heymann SJ, Ndung'u T, Gaseitsiwe S, Novitsky V, Makhema J, Lagakos S, Essex M. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS. 2006 Jun 12;20(9):1281-8. doi: 10.1097/01.aids.0000232236.26630.35.
- Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M; PHPT-5 Team. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.
- Lallemant M, Le Coeur S, Sirirungsi W, Cressey TR, Ngo-Giang-Huong N, Traisathit P, Klinbuayaem V, Sabsanong P, Kanjanavikai P, Jourdain G, Mcintosh K, Koetsawang S; PHPT-5 study investigators. Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand. AIDS. 2015 Nov 28;29(18):2497-507. doi: 10.1097/QAD.0000000000000865.
- Sripan P, Le Coeur S, Amzal B, Ingsrisawang L, Traisathit P, Ngo-Giang-Huong N, McIntosh K, Cressey TR, Sangsawang S, Rawangban B, Kanjanavikai P, Treluyer JM, Jourdain G, Lallemant M, Urien S. Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV. PLoS One. 2015 May 19;10(5):e0126647. doi: 10.1371/journal.pone.0126647. eCollection 2015. Erratum In: PLoS One. 2015;10(6):e0130917. PLoS One. 2015;10(8):e0137368.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Nevirapine
- Ritonavir
- Lopinavir
- Zidovudine
Other Study ID Numbers
- PHPT-5 First Phase
- R01HD052461 (U.S. NIH Grant/Contract)
- R01HD056953 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Maternal and infant nevirapine
-
National Defense Medical Center, TaiwanUnknownFatigue | Stress | Body Composition | Postpartum | AttachmentTaiwan
-
Johns Hopkins Bloomberg School of Public HealthUnited States Agency for International Development (USAID)CompletedAnemia | Wasting | Stunting | UnderweightIndia
-
Bilecik Seyh Edebali UniversitesiRecruitingPremature Birth | Postpartum Depression | Breast Feeding | Self Efficacy | Theory, Double BindTurkey
-
59th Medical WingCompleted
-
Michigan State UniversitySpectrum Health HospitalsCompletedStress | Child Development | Perinatal Depression | Prenatal Health Risk BehaviorsUnited States
-
University of PaviaNot yet recruitingChildhood Obesity | Life Style | Intestinal Microbiome
-
CHU de ReimsCompletedPremature Birth | Mother's Post-traumatic Reaction | Mother-infant InteractionsFrance
-
University of RochesterNational Institute of Mental Health (NIMH)Completed
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsPhilippines, Mexico, Thailand, Brazil, Colombia, Panama, South Africa, Argentina, Bangladesh, Malaysia
-
Centers for Disease Control and PreventionUniversity of North Carolina, Chapel Hill; Kamuzu Central HospitalCompleted